51 related articles for article (PubMed ID: 15356688)
1. [Overdiagnosis in mammography screening].
Zahl PH; Maehlen J
Tidsskr Nor Laegeforen; 2004 Sep; 124(17):2238-9. PubMed ID: 15356688
[TBL] [Abstract][Full Text] [Related]
2. A case-control study to evaluate the impact of the breast screening programme on breast cancer incidence in England.
Blyuss O; Dibden A; Massat NJ; Parmar D; Cuzick J; Duffy SW; Sasieni P
Cancer Med; 2023 Jan; 12(2):1878-1887. PubMed ID: 35851849
[TBL] [Abstract][Full Text] [Related]
3. Overdiagnosis of breast cancer in the Norwegian Breast Cancer Screening Program estimated by the Norwegian Women and Cancer cohort study.
Lund E; Mode N; Waaseth M; Thalabard JC
BMC Cancer; 2013 Dec; 13():614. PubMed ID: 24377727
[TBL] [Abstract][Full Text] [Related]
4. Estimating Breast Cancer Overdiagnosis After Screening Mammography Among Older Women in the United States.
Richman IB; Long JB; Soulos PR; Wang SY; Gross CP
Ann Intern Med; 2023 Sep; 176(9):1172-1180. PubMed ID: 37549389
[TBL] [Abstract][Full Text] [Related]
5. Atypia detected during breast screening and subsequent development of cancer: observational analysis of the Sloane atypia prospective cohort in England.
Freeman K; Jenkinson D; Clements K; Wallis MG; Pinder SE; Provenzano E; Stobart H; Stallard N; Kearins O; Sharma N; Shaaban A; Kirwan CC; Hilton B; Thompson AM; Taylor-Phillips S;
BMJ; 2024 Feb; 384():e077039. PubMed ID: 38302129
[TBL] [Abstract][Full Text] [Related]
6. Estimate of overdiagnosis of breast cancer due to mammography after adjustment for lead time. A service screening study in Italy.
Paci E; Miccinesi G; Puliti D; Baldazzi P; De Lisi V; Falcini F; Cirilli C; Ferretti S; Mangone L; Finarelli AC; Rosso S; Segnan N; Stracci F; Traina A; Tumino R; Zorzi M
Breast Cancer Res; 2006; 8(6):R68. PubMed ID: 17147789
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer mortality in participants of the Norwegian Breast Cancer Screening Program.
Hofvind S; Ursin G; Tretli S; Sebuødegård S; Møller B
Cancer; 2013 Sep; 119(17):3106-12. PubMed ID: 23720226
[TBL] [Abstract][Full Text] [Related]
8. Implications of Overdiagnosis: Impact on Screening Mammography Practices.
Morris E; Feig SA; Drexler M; Lehman C
Popul Health Manag; 2015 Sep; 18 Suppl 1(Suppl 1):S3-11. PubMed ID: 26414384
[TBL] [Abstract][Full Text] [Related]
9. Comparisons of assessment pathways after abnormal mammography screening in Denmark, Norway, and Spain.
Jørgensen SF; Sagstad S; Louro J; Román M; Castells X; Hofvind S; Njor S
Breast Cancer Res Treat; 2024 May; 205(1):135-145. PubMed ID: 38285110
[TBL] [Abstract][Full Text] [Related]
10. Overdiagnosis associated with breast cancer screening: A simulation study to compare lead-time adjustment methods.
Seigneurin A; Labarère J; Duffy SW; Colonna M
Cancer Epidemiol; 2015 Dec; 39(6):1128-35. PubMed ID: 26341587
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer incidence and mortality in Tyrol/Austria after fifteen years of opportunistic mammography screening.
Oberaigner W; Buchberger W; Frede T; Knapp R; Marth C; Siebert U
BMC Public Health; 2010 Feb; 10():86. PubMed ID: 20170536
[TBL] [Abstract][Full Text] [Related]
12. An investigation of the apparent breast cancer epidemic in France: screening and incidence trends in birth cohorts.
Junod B; Zahl PH; Kaplan RM; Olsen J; Greenland S
BMC Cancer; 2011 Sep; 11():401. PubMed ID: 21936933
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of health benefits and harms of the breast cancer screening programme in the Basque Country using discrete event simulation.
Arrospide A; Rue M; van Ravesteyn NT; Comas M; Larrañaga N; Sarriugarte G; Mar J
BMC Cancer; 2015 Oct; 15():671. PubMed ID: 26459293
[TBL] [Abstract][Full Text] [Related]
14. The influence of breast screening on breast cancer incidence in England: observational study based on cancer registries and bulletins of the NHS Breast Screening Programme.
Autier P; Ould Ammar R; Bota M
Eur J Public Health; 2024 Apr; ():. PubMed ID: 38687973
[TBL] [Abstract][Full Text] [Related]
15. Overdiagnosis in breast cancer screening: the importance of length of observation period and lead time.
Duffy SW; Parmar D
Breast Cancer Res; 2013 May; 15(3):R41. PubMed ID: 23680223
[TBL] [Abstract][Full Text] [Related]
16. Fatal and non-fatal breast cancers in women targeted by BreastScreen Norway: a cohort study.
Tsuruda KM; Hoff SR; Akslen LA; Hofvind S
Br J Cancer; 2024 Jan; 130(1):99-107. PubMed ID: 38049556
[TBL] [Abstract][Full Text] [Related]
17. Perspectives on the Overdiagnosis of Breast Cancer Associated with Mammographic Screening.
Helvie MA
J Breast Imaging; 2019 Dec; 1(4):278-282. PubMed ID: 38424804
[TBL] [Abstract][Full Text] [Related]
18. Use of surveillance mammography among older patients with a history of breast cancer.
Berger E; Long JB; Sheffrin M; Lindsay M; Richman IB
J Geriatr Oncol; 2024 Apr; 15(3):101686. PubMed ID: 38114335
[No Abstract] [Full Text] [Related]
19. Behaviour within a Clinical Trial and Implications for Mammography Guidelines.
Kowalski AE
Rev Econ Stud; 2023 Jan; 90(1):432-462. PubMed ID: 36798741
[TBL] [Abstract][Full Text] [Related]
20. Reply to Yaffe, M.J. Correction for Self-Selection in Breast Cancer Screening. Comment on "Dibden et al. Worldwide Review and Meta-Analysis of Cohort Studies Measuring the Effect of Mammography Screening Programmes on Incidence-Based Breast Cancer Mortality.
Dibden A; Offman J; Duffy SW; Gabe R
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
